Benitec Biopharma Sets Virtual 2025 Annual Meeting, Key Votes Ahead
Ticker: BNTC · Form: DEF 14A · Filed: Oct 14, 2025 · CIK: 1808898
| Field | Detail |
|---|---|
| Company | Benitec Biopharma INC. (BNTC) |
| Form Type | DEF 14A |
| Filed Date | Oct 14, 2025 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.0001, $0.0017, $3.86 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Corporate Governance, Director Election, Executive Compensation, Shareholder Vote, Biopharma, Virtual Meeting
Related Tickers: BNTC
TL;DR
**BNTC's virtual annual meeting on December 1st is a must-watch for investors, with director elections and a Say-on-Pay vote that could signal future dilution risks from those 15.2M pre-funded warrants.**
AI Summary
Benitec Biopharma Inc. (BNTC) is holding its 2025 Annual Meeting of Stockholders virtually on December 1, 2025, at 1:00 p.m. Pacific Time. Key proposals include the election of two Class III directors to serve until the 2028 Annual Meeting, the ratification of the independent registered public accounting firm for the fiscal year ending June 30, 2026, and a non-binding advisory vote on executive compensation (Say-on-Pay). As of the record date, October 10, 2025, there were 26,250,469 shares of common stock issued and outstanding. This figure excludes 15,270,806 unexercised pre-funded warrants, which, if exercised, would significantly dilute existing shareholders. The company emphasizes the importance of stockholder participation, offering virtual attendance, internet, and telephone voting options. Dr. Jerel Banks, CEO and Chairman, signed the proxy statement, urging stockholders to vote.
Why It Matters
This DEF 14A filing outlines critical governance decisions for Benitec Biopharma, directly impacting investor confidence and future strategic direction. The election of two Class III directors will shape the board's composition and oversight for the next three years, influencing long-term company strategy and executive accountability. The Say-on-Pay vote, while non-binding, provides a crucial signal from investors regarding executive compensation, potentially affecting management's incentives and retention. Furthermore, the significant number of unexercised pre-funded warrants (15,270,806 shares) represents potential future dilution for existing shareholders, a competitive disadvantage if not managed effectively, and could impact the company's ability to attract new capital.
Risk Assessment
Risk Level: medium — The company has 15,270,806 unexercised pre-funded warrants outstanding as of October 10, 2025, which, upon exercise, will dilute existing shareholders. While the nominal exercise price suggests eventual exercise, this represents a substantial potential increase in outstanding shares beyond the current 26,250,469 shares, posing a medium-term dilution risk.
Analyst Insight
Investors should carefully review the director nominees and executive compensation details, casting their votes to align with their long-term interests. Given the potential dilution from 15,270,806 pre-funded warrants, shareholders should also scrutinize any future capital raise plans and their impact on share value.
Key Numbers
- 26,250,469 — Shares of common stock outstanding (As of the record date, October 10, 2025)
- 15,270,806 — Unexercised pre-funded warrants (Potential shares to be issued, excluding from current outstanding shares)
- 2 — Number of Class III directors (To be elected at the 2025 Annual Meeting)
- 1:00 p.m. — Annual Meeting start time (Pacific Time on December 1, 2025)
- 90 — Days prior to annual meeting (Minimum notice for stockholder proposals under bylaws)
- 120 — Days prior to annual meeting (Maximum notice for stockholder proposals under bylaws)
- 60 — Calendar days prior to anniversary (Deadline for universal proxy rule notice for 2026 Annual Meeting)
- $0.0001 — Par value per share (Common stock par value)
Key Players & Entities
- Benitec Biopharma Inc. (company) — Registrant for DEF 14A filing
- Dr. Jerel Banks (person) — Chief Executive Officer and Chairman of the Board of Directors
- Securities and Exchange Commission (regulator) — Oversees filing requirements
- Baker Tilly LLP (company) — Independent registered public accounting firm
- Hayward, California (location) — Company headquarters
- December 1, 2025 (date) — Date of 2025 Annual Meeting of Stockholders
- October 10, 2025 (date) — Record date for voting eligibility
- June 30, 2026 (date) — Fiscal year-end for accounting firm ratification
- October 17, 2025 (date) — Approximate mailing date of proxy materials
- Delaware (location) — State of incorporation
FAQ
When is Benitec Biopharma's 2025 Annual Meeting of Stockholders?
Benitec Biopharma Inc.'s 2025 Annual Meeting of Stockholders will be held virtually on December 1, 2025, beginning at 1:00 p.m., Pacific Time. Stockholders can access the meeting online at www.meetnow.global/M4KC5WC.
What are the key proposals to be voted on at the Benitec Biopharma Annual Meeting?
The key proposals include the election of two Class III directors, the ratification of the appointment of the independent registered public accounting firm for the fiscal year ending June 30, 2026, and a non-binding advisory vote on the compensation of the Company's named executive officers (Say-on-Pay).
Who is eligible to vote at the Benitec Biopharma 2025 Annual Meeting?
Only holders of record of Benitec Biopharma's common stock at the close of business on October 10, 2025, the Record Date, are entitled to notice of and to vote at the Annual Meeting. As of this date, there were 26,250,469 shares of common stock issued and outstanding.
How can Benitec Biopharma stockholders vote their shares?
Stockholders can vote online at the virtual Annual Meeting, by telephone, electronically through the Internet by following instructions on their proxy materials, or by completing, dating, signing, and returning their proxy card. Instructions are available at www.investorvote.com/BNTC.
What is the impact of pre-funded warrants on Benitec Biopharma's stock?
As of October 10, 2025, Benitec Biopharma had 15,270,806 unexercised pre-funded warrants outstanding. These warrants, upon exercise, will increase the total number of shares of common stock outstanding, potentially diluting the ownership percentage of existing shareholders.
Who is the CEO and Chairman of Benitec Biopharma Inc.?
Dr. Jerel Banks serves as both the Chief Executive Officer and Chairman of the Board of Directors for Benitec Biopharma Inc. He signed the proxy statement for the 2025 Annual Meeting.
What is the deadline for stockholder proposals for Benitec Biopharma's 2026 Annual Meeting?
For inclusion in proxy materials, proposals for Benitec Biopharma's 2026 Annual Meeting must be received by the Corporate Secretary not later than June 19, 2026. For other proposals, notice must be delivered between August 3, 2026, and September 2, 2026, based on the 2025 meeting date.
What is a 'Say-on-Pay' vote for Benitec Biopharma?
A 'Say-on-Pay' vote is a non-binding advisory vote on the compensation of Benitec Biopharma's named executive officers, as disclosed in the proxy statement. It allows stockholders to express their approval or disapproval of executive compensation practices.
Will Benitec Biopharma's independent accounting firm be ratified at the Annual Meeting?
Yes, Proposal 2 at Benitec Biopharma's 2025 Annual Meeting is for the ratification of Baker Tilly LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2026. This is considered a 'routine' proposal.
How many directors are being elected at the Benitec Biopharma 2025 Annual Meeting?
Two Class III directors are being elected at Benitec Biopharma's 2025 Annual Meeting of Stockholders. These directors will hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected and qualified.
Industry Context
Benitec Biopharma operates in the biotechnology sector, focusing on developing therapies for serious human diseases. This industry is characterized by high research and development costs, long development cycles, and significant regulatory hurdles. Companies in this space often rely on substantial funding rounds and strategic partnerships to advance their pipelines.
Regulatory Implications
As a biopharmaceutical company, Benitec is subject to stringent regulations from bodies like the FDA. Approval processes for new therapies are lengthy and costly, and any adverse findings or delays can significantly impact the company's prospects. Compliance with evolving healthcare regulations and data privacy laws is also critical.
What Investors Should Do
- Review the proposals for the 2025 Annual Meeting.
- Consider the potential dilution from unexercised pre-funded warrants.
- Vote your shares.
Key Dates
- 2025-12-01: 2025 Annual Meeting of Stockholders — Stockholders will vote on key proposals including director elections, ratification of auditors, and executive compensation.
- 2025-10-10: Record Date for Annual Meeting — Establishes the list of stockholders entitled to vote at the Annual Meeting.
- 2025-10-17: Mailing of Notice of Internet Availability of Proxy Materials and Proxy Statement — Commencement of the proxy solicitation period for the Annual Meeting.
Glossary
- DEF 14A
- A proxy statement filing with the SEC that provides detailed information about matters to be voted on at a company's annual meeting. (This document contains the information being analyzed, outlining proposals and company details for the annual meeting.)
- Class III directors
- Directors whose terms expire at the third annual meeting following their election. (Two Class III directors are up for election at the 2025 Annual Meeting, requiring stockholder votes.)
- Pre-funded warrants
- A type of warrant that allows the holder to purchase shares at a nominal price, often used in financing to avoid immediate dilution. (The 15,270,806 unexercised pre-funded warrants represent significant potential dilution if exercised.)
- Say-on-Pay
- A non-binding shareholder vote on the compensation of the company's named executive officers. (Stockholders will have an advisory vote on executive compensation, allowing them to express their views.)
- Par value
- A nominal value assigned to a share of stock, often very low, as stated in the company's charter. (The common stock has a par value of $0.0001 per share.)
Year-Over-Year Comparison
Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available in the provided text from the DEF 14A filing.
Filing Stats: 4,712 words · 19 min read · ~16 pages · Grade level 13.2 · Accepted 2025-10-14 16:58:35
Key Financial Figures
- $0.0001 — n shares of our common stock, par value $0.0001 per share, as of the Record Date, which
- $0.0017 — of Common Stock at an exercise price of $0.0017 per share, subject to the limitations o
- $3.86 — of Common Stock at an exercise price of $3.86 per share. The address of the principal
Filing Documents
- d32674ddef14a.htm (DEF 14A) — 366KB
- g32674g10a01.jpg (GRAPHIC) — 36KB
- g32674g10a02.jpg (GRAPHIC) — 2KB
- g32674g10a03.jpg (GRAPHIC) — 23KB
- g32674g10a04.jpg (GRAPHIC) — 2KB
- g32674g10a05.jpg (GRAPHIC) — 2KB
- g32674g10a06.jpg (GRAPHIC) — 4KB
- g32674g10a08.jpg (GRAPHIC) — 3KB
- g32674g10a09.jpg (GRAPHIC) — 12KB
- g32674g10a10.jpg (GRAPHIC) — 11KB
- g32674g10t14.jpg (GRAPHIC) — 15KB
- g32674g36w34.jpg (GRAPHIC) — 29KB
- g32674g59c16.jpg (GRAPHIC) — 28KB
- 0001193125-25-239131.txt ( ) — 1241KB
- bntc-20250630.xsd (EX-101.SCH) — 9KB
- d32674ddef14a_htm.xml (XML) — 104KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 17 March 2025 Financing Transaction 15 Summary Compensation Table 17 Narrative Disclosure to Summary Compensation Table 18 Outstanding Equity Awards at Fiscal Year-End 20 Other Elements of Compensation 21 Pay Versus Performance Disclosure 22 Relationship Between Financial Performance Measures and CAP 23 Equity Compensation Plan Information 24 DIRECTOR COMPENSATION 25 Narrative Disclosure to Director Compensation Table 25 PROPOSAL 1—ELECTION OF DIRECTORS 27 Required Vote 27 Board Recommendation 27 i Table of Contents Page PROPOSAL 2—RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 28 Required Vote 28 Board Recommendation 29 AUDIT COMMITTEE REPORT 30 PROPOSAL 3—ADVISORY VOTE ON EXECUTIVE COMPENSATION 31 Required Vote 31 Board Recommendation 31 ANNUAL REPORT TO STOCKHOLDERS 32 OTHER MATTERS 32 DELIVERY OF DOCUMENTS TO STOCKHOLDERS SHARING AN ADDRESS 32 ii Table of Contents 3940 Trust Way Hayward, California 94545 2025 ANNUAL MEETING PROXY STATEMENT We are making these proxy materials available to you in connection with the solicitation of proxies by the Board of Directors (the "Board") of Benitec Biopharma Inc. for the 2025 Annual Meeting of Stockholders (the "Annual Meeting") to be held virtually on December 1, 2025 at 1:00 p.m., Pacific Time, and for any adjournment or postponement of the Annual Meeting. The Annual Meeting can be accessed by visiting www.meetnow.global/M4KC5WC, where you will be able to listen to the meeting live, submit questions, and vote online. The mailing of the Notice of Internet Availability of Proxy Materials and the Proxy Statement and Annual Report will commence on or about October 17, 2025. Electronic copies of this Proxy Statement and the Annual Report for the year ended June 30, 2025 are available at www.investorvote.com/BNTC and on the Internet through the Securities and Exc